ArticleMembranes2023
The Selection of Efficient Antiscalant for RO Facility, Control of Its Quality and Evaluation of the Economical Efficiency of Its Application.
Article in Membranes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Adsorption of polymeric inhibitor molecules to calcium carbonate crystal surface was investigated. Inhibiting efficiencies of phosphonic acid-based antiscalants are dependent on the amount of adsorbed material on the growing crystal surface. A strong antiscalant even at a small dose provides the necessary rate of adsorption. Comparison of two phosphonic-based antiscalants was made both in laboratory and industrial conditions. A distinguishing feature of the strong antiscalant is the presence of aminotris (metylene-diphosphonic acid) ATMP. Experimental dependencies of antiscalant adsorption rates on the antiscalant dosage values were determined. Emphasis is given to the use of nanofiltration membranes that possess lower scaling propensities. Modernization is presented to reduce operational costs due to antiscalant and nanofiltration membranes. The main conclusion is that control of scaling should be implemented together with the use of nanofiltration membranes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.